Results 31 to 40 of about 703,665 (265)

Targeting RIP Kinases in Chronic Inflammatory Disease

Biomolecules, 2021
Chronic inflammatory disorders are characterised by aberrant and exaggerated inflammatory immune cell responses. Modes of extrinsic cell death, apoptosis and necroptosis, have now been shown to be potent drivers of deleterious inflammation, and mutations
Mary Speir, Tirta M. Djajawi, Stephanie A. Conos, Hazel Tye, Kate E. Lawlor   +4 more
doaj   +1 more source

Change in Eosinophil Count in Patients with Heart Failure Treated with Anakinra

Cells, 2023
Background: Interleukin-1 blockade with anakinra leads to a transient increase in eosinophil blood count (eosinophils) in patients with acute myocardial infarction. We aimed to investigate the effect of anakinra on changes in eosinophils in patients with
Michele Golino, Francesco Moroni, Marco Giuseppe Del Buono, Justin M. Canada, Azita H. Talasaz, Sebastian Piñel, James Mbualungu, Alessandra Vecchiè, Ai-Chen (Jane) Ho, Georgia K. Thomas, Salvatore Carbone, Hayley E. Billingsley, Jeremy Turlington, Roshanak Markley, Cory Trankle, Roberto De Ponti, Benjamin Van Tassell, Antonio Abbate   +17 more
doaj   +1 more source

Serum interleukin 1 and interleukin 10 levels in Iraqi leukemic patients with hepatitis G virus infection.

مجلة كلية الطب, 2013
Background: Objectives : This prospective   study aimed to  estimate interleukins 1 and 10  levels in acute  hepatitis (G) in Iraqi patients with leukemiaHepatitis G virus and GB virus C (GBV-C)  RNA viruses that were independently identified in 1995,
Muhammad M. Alani
doaj   +1 more source

The Legacy of Sickness Behaviors

Frontiers in Psychiatry, 2020
Systemic infections of all types lead to a syndrome known as sickness behaviors. Changes in the behavior of febrile humans and animals formed the original basis for this concept.
Keith W. Kelley, Keith W. Kelley, Keith W. Kelley, Stephen Kent, Stephen Kent   +4 more
doaj   +1 more source

Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer

OncoImmunology, 2019
Bermekimab is a true human monoclonal antibody that targets interleukin-1alpa (IL-1α), an inflammation-mediating alarmin. IL-1 receptor antagonist (IL-1Ra) is a natural molecule that blocks IL-1α activity by occupying the IL-1 receptor.
Razelle Kurzrock, Tamas Hickish, Lucjan Wyrwicz, Mark Saunders, Qian Wu, Michael Stecher, Prasant Mohanty, Charles A. Dinarello, John Simard   +8 more
doaj   +1 more source

Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation

Frontiers in Immunology, 2021
BackgroundRestraining maladaptive inflammation is considered a rationale strategy to treat severe coronavirus disease-19 (COVID-19) but available studies with selective inhibitors of pro-inflammatory cytokines have not provided unequivocal evidence of ...
Emanuel Della-Torre, Emanuel Della-Torre, Marco Lanzillotta, Corrado Campochiaro, Corrado Campochiaro, Giulio Cavalli, Giulio Cavalli, Giacomo De Luca, Giacomo De Luca, Alessandro Tomelleri, Alessandro Tomelleri, Nicola Boffini, Nicola Boffini, Rebecca De Lorenzo, Annalisa Ruggeri, Annalisa Ruggeri, Patrizia Rovere-Querini, Patrizia Rovere-Querini, Antonella Castagna, Antonella Castagna, Giovanni Landoni, Giovanni Landoni, Moreno Tresoldi, Fabio Ciceri, Fabio Ciceri, Alberto Zangrillo, Alberto Zangrillo, Lorenzo Dagna, Lorenzo Dagna   +28 more
doaj   +1 more source

Targeting interleukin-22 for cancer therapy

Human Vaccines & Immunotherapeutics, 2018
Interleukin-22 (IL-22) is a member of IL-10 family of cytokines. IL-22 induces proliferative and anti-apoptotic signaling pathways and production of anti-microbial molecules that enhance tissue regeneration and host defense.
Anamarija Markota, Stefan Endres, Sebastian Kobold   +2 more
doaj   +1 more source

Contributions of Interleukin-1 Receptor Signaling in Traumatic Brain Injury

Frontiers in Behavioral Neuroscience, 2020
Traumatic brain injury (TBI) in various forms affects millions in the United States annually. There are currently no FDA-approved therapies for acute injury or the chronic comorbidities associated with TBI.
Jason G. Thome, Evan L. Reeder, Sean M. Collins, Poornima Gopalan, Matthew J. Robson   +4 more
doaj   +1 more source

What Is IL-1 for? The Functions of Interleukin-1 Across Evolution

Frontiers in Immunology, 2022
Interleukin-1 is a cytokine with potent inflammatory and immune-amplifying effects, mainly produced by macrophages during defensive reactions. In mammals, IL-1 is a superfamily of eleven structurally similar proteins, all involved in inflammation or its ...
Diana Boraschi, Diana Boraschi, Diana Boraschi   +2 more
doaj   +1 more source

The interleukin-1 receptor antagonist influences interleukin-1 effects in rat and mouse

Mediators of Inflammation, 1992
In this work we have focused on the ability of interleukin-1 to induce an acute phase protein response and a degranulation of polymorphonuclear leukocytes in vivo.
P. Bjrök, K. Ohlsson
doaj   +1 more source